Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

• Status: Completed
• Trial end date: 2015-06-30

Summary

This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and RRM1 of the tumor cells.

• Phase: Phase 2

Details

• Lead Sponsor: Yonsei University
• Treatments: Carboplatin; Docetaxel; Gemcitabine; Vinblastine; Vinorelbine